Evolve Biologics
Alison Renner has a diverse work experience in various roles and industries. Alison started their career as a Research Assistant at the University of Missouri-Kansas City, where they worked on an osteoporosis/bone density study using mice models. Alison later joined Kansas State University, serving as a Learning Assistant Coach and a member of the Prosthetic Design Team. During this time, they also led a project to develop a housing device for a microfluidic smartphone diagnostic system.
Alison then gained industry experience at Automatic Systems, Inc., where they worked as a Mechanical Engineering Intern. Alison further expanded their skills at Pfizer, initially as a Process Engineer in the Rotational Development Program, and later as a Capital Projects Process Engineer. In these roles, they managed capital projects, provided technical oversight, resolved technical issues, and achieved cost reduction goals.
Their most recent position was with Evolve Biologics, where they worked as a Process Engineer. Alison played a key role in building and designing a new plasma-derived therapy manufacturing site. Alison was responsible for making detailed design decisions, ensuring system safety, and collaborating with design firms.
Overall, Alison Renner has a strong background in engineering, research, project management, and process optimization, making their a highly skilled and versatile professional.
Alison Renner completed their Bachelor's degree in Biological Systems Engineering from Kansas State University, where they studied from 2016 to 2020. In addition to their degree, they also obtained the Certified SOLIDWORKS Associate (CSWA) certification from Kansas State University in May 2018. Alison further expanded their education by obtaining a Lean Six Sigma Yellow Belt (ICYB) certification from Pfizer in April 2021. Recently, in May 2022, they earned a Master Certificate in Project Management from Wichita State University.
This person is not in any offices
Evolve Biologics
Evolve Biologics Inc. offers the development and commercialization of plasma-derived therapeutics, using its proprietary PlasmaCap EBA purification technology to more efficiently and effectively meet growing global patient demand for these life-saving products. The Company is currently in the process of commercializing an exciting and innovativeportfolio of product candidates, including IVIG (intravenous immunoglobulin) and Albumin (human serum albumin), both of which are in advanced stages of regulatory approval in the US (FDA) and Canada (Health Canada).